Differential expression of bcl-2 family proteins in bladder carcinomas relationship with apoptotic rate and survival

European Urology

Volumn 41, Issue 3, 2002, Pages 274-283

  Korkolopoulou, Penelope ^a,c   Lazaris, Andreas Ch ^a   Konstantinidou, Anastasia E ^a   Kavantzas, Nikolaos ^a   Patsouris, Efstratios ^a   Christodoulou, Panayota ^b   Thomas Tsagli, Euphemia ^b   Davaris, Panagiotis ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c 73 ^*  (Greece)

Author keywords

Apoptosis; bax; bcl 2; bcl xl; bcl xs; Bladder; Urothelial carcinoma

Indexed keywords

KI 67 ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN BCL XL; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; DNA DETERMINATION; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; RELAPSE; STATISTICAL SIGNIFICANCE; SURVIVAL; UROTHELIUM;

AGED; APOPTOSIS; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0036522622     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00003-9     Document Type: Article

References (37)

1. Williams GT. Programmed cell death: Apoptosis and oncogenesis. Cell 1991;65:1097-8.
2. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
3. Oltvai ZN, Korsmeyer SJ. Checkpoints of dueling dimers foil death wishes. Cell 1994;79:189-92.
4. Ruoslahti E, Reed JC. Anchorage dependence, integrins and apoptosis. Cell 1994;77:477-8.
5. Reed JC. Bcl-2: Prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 1995;9:451-74.
6. Ryan JJ, Prochownik E, Gottlieb CA, Apel IJ, Merino R, Nunez J, Clarke MF. C-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci USA 1994;91:5878-82.
7. Vollmer RT, Humphrey PA, Swanson PE, Wick MR, Hudson LA. Invasion of the bladder by transitional cell carcinoma. Its relation to histologic grade and expression of p53, MIB-1, c-erbB-2, epidermal growth factor receptor and bcl-2. Cancer 1998;82:715-23.
8. Hermanek P, Sobin LH. TNM Classification of Malignant Tumours. 4th Ed. Berlin: Springer, 1992.
9. Epstein JI, Amin MB, Reuter VR, Mostofi FK. Bladder consensus conference committee. The World Health Organization/International Society of Urological Pathology Consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998;22:1435-48.
10. Shi S-R, Key ME, Kalra KL. Antigen retrieval in formalin-fixed paraffin-embedded tissues. An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741-8.
11. Korkolopoulou P, Konstantinidou A-E, Christodoulou P, Patsouris E, Thomas-Tsangli E, Kapralos P, Davaris P. Apoptosis in bladder carcinomas detected with monoclonal antibody to single-stranded DNA. Relation to cell cycle regulators and survival. Urology 2000;56:516-20.
12. King ED, Matteson J, Jacobs SC, Kyprianou N. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder. Association with tumour progression. J Urol 1996;155:316-20.
13. Frankfurt OS, Robb JA, Sugarbaker EV, Villa L. Apoptosis in breast carcinomas detected with monoclonal antibody to single-stranded DNA. Relation to bcl-2 expression. Clin Cancer Res 1997;3:465-71.
14. Lipponen PK, Aaltomaa S, Eskelinen M. Expression of the apoptosis suppressing bcl-2 protein in transitional cell bladder tumours. Histopathology 1996;28:135-40.
15. Esrig D, Spruck III CH, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen SC, Skinner DG, Jones PA, Cote RJ. p53 Nuclear protein accumulation correlates with mutations in the p53 gene, tumour grade and stage in bladder cancer. Am J Pathol 1993;143:1289-397.
16. Kirsch EJ, Baunoch DA, Stadler WM. Expression of bcl-2 and bcl-X in bladder cancer. J Urol 1998;159:1348-53.
17. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC. Immunohistochemical analysis of bcl-2, bax, bcl-X and mcl-l expresion in prostate cancers. Am J Pathol 1996;148:1567-76.
18. Gazzaniga P, Gradilone A, Vercillo R, Gandini O, Silvestri I, Napolitano M, Alboncini L, Vincenzoni A, Gallucci M, Frati L, Agliano AM. Bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer. Int J Cancer 1996;69:100-4.
19. Ye D, Li H, Qian S, Sun Y, Zheng J, Ma Y. Bcl-2/bax expression and p53 gene status in human bladder cancer. Relationship to early recurrence with intravesical chemotherapy after resection. J Urol 1998;160:2025-9.
20. Krajewska M, Fenoglio-Preiser CM, Krajewski S, Song K, Macdonald JS, Stemmerman G, Reed JC. Immunohistochemical analysis of bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol 1996;149:1449-57.
21. Frankfurt OS, Robb JA, Sugarbaker EV, Villa L. Monoclonal antibody to single-stranded DNA is a specific and cellular marker of apoptosis. Exp Cell Res 1996;226:387-97.
22. Lipponen PK, Aaltomaa S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol 1994;173:333-9.
23. Shiina H, Igawa M, Shigeno K, Yamasaki Y, Urakami S, Yoneda T, Wada Y, Honda S, Nagashaki M. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis. Oncology 1999;56:239-47.
24. Bell DA. Morrison B. The spontaneous apoptotic cell death of normal human lymphocytes in vitro: The release of, and immuno-proliferative response to, nucleosomes in vitro. Clin Immunol Immunopathol 1991;60:13-26.
25. Furihata M, Sonobe H, Ohtsuki Y, Yamashita M, Morioka M, Yamamoto A, Terao N, Kuwahara M, Fujisaki N. Detection of p53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia. J Pathol 1996;178:133-9.
26. Tzai T-S, Chow N-H, Lin JS-N, Yang W-H, Tong Y-C. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy. Anticancer Res 1998;18:4717-22.
27. Wu TT, Chen J-H, Lee Y-H, Huang J-K. The role of bcl-2, p53 and Ki-67 index in predicting tumour recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 2000;163:758-60.
28. Nakopoulou L, Vourlakou C, Zervas A, Tzonou A, Gakiopoulou H, Dimopoulos M-A. The prevalence of bcl-2, p53 and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol 1998;29:146-54.
29. Shiina H, Igawa M, Urakami S, Honda S, Shirakawa H, Ishibe T. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder. J Clin Pathol 1996;49:395-9.
30. Okamura T, Akita H, Kawai N, Tozawa K, Yamada Y, Kohri K. Immunohistochemical evaluation of p53, proliferating cell nuclear antigen (PCNA) and bcl-2 expression during bacillus calmette-guerin (BCG) intravesical instillation therapy for superficial bladder cancers. Urol Res 1998;26:161-4.
31. Li B, Kanamaru H, Noriki S, Yamaguchi T, Fukuda M, Okada K. Reriprocal expression of bcl-2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder. Urol Res 1998;26:235-41.
32. Bilim V, Tomita Y, Kawasaki T, Katagiri A, Imai T, Takeda M, Takahashi K. Prognostic value of bcl-2 and p53 expression in urinary tract transitional cell cancer. J Natl Cancer Inst 1996;88:686-8.
33. Gazzaniga P, Gradilone A, Silvestri I, Gandini O, Giuliani L, Vincenzoni A, Gallucci M, Frati L, Agliano AM. Variable levels of bcl-2, bcl-X and bax mRNA in bladder cancer progression. Oncol Rep 1998;5:901-4.
34. Krajewska M, Moss SF, Krajewski S, Song K, Holt PR, Reed JC. Elevated expression of bcl-X and reduced bax in primary colorectal adenocarcinomas. Cancer Res 1996;56:2422-7.
35. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC. Reduced expression of proapoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995;55:4471-8.
36. Glick SH, Howell LP, White RWD. Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. J Urol 1996;155:1754-7.
37. Pryor JP. Factors influencing the survival of patients with transitional cell tumours of the urinary bladder. Br J Urol 1973;45:586-91.